Product Code: RP-ID-10352433 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10352433
Market Overview:
Phenytoin Testing Market Analysis by Product Type (Laboratory Test, Test Kits, Reagent, and Accessories); and by End-User (Hospitals, Pathological Laboratories, and Research Centers)-Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Global Phenytoin Testing Market Report Scope
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~2% |
|
Base Year Market Size (2022) |
~ USD 7 Billion |
|
Forecast Year Market Size (2033) |
~ USD 8 Billion |
Global Phenytoin Testing Market Highlights Over 2023 - 2033
The global phenytoin testing market is estimated to garner a revenue of about ~USD 8 billion by the end of 2033 by growing at a CAGR of ~2% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of about ~USD 7 billion in the year 2022. A primary growth factor for the phenytoin testing market is the rise in the incidences of phenytoin toxicity. The 2019 annual report on poisoning by the American Association of Poison Control Centers (AAPCC) recorded more than 1260 cases of single-substance phenytoin exposure.
GET A SAMPLE COPY OF THIS REPORT
Phenytoin is a widely used anticonvulsant drug that also prevents and treats seizures during or following surgery to the nervous system or the brain. The drug works by reducing uncontrolled electrical disturbances in the brain. However, an increase in the everyday dosage, switching from one formulation or brand to another, and a frequency change in drug administration, sometimes lead to phenytoin toxicity. According to the National Centre for Biotechnology Information (NCBI), in a few occurrences of phenytoin toxicity, death happens if the patient does not receive prompt treatment. NCBI adds that over 50% experience minor morbidity while approximately 10-20% suffer from severe morbidities. Early detection of possible phenytoin toxicity prevents and manages further poisoning. Thus, increasing cases of phenytoin toxicity is one of the chief causes for the expansion of the phenytoin testing market. The market growth can also be attributed to the increased prescription rates, standard dose control measures, and efficacy testing.
Global Phenytoin Testing Market: Growth Drivers and Challenges
Growth Drivers
-
Immense Significance in Preventing Damage to Kidneys and Nervous System– In patients of epilepsy who are not on overdose, phenytoin toxicity can indicate renal failure. Uremia and hypoalbuminemia, both conditions related to kidney disease, can reduce the amount of bound phenytoin in the plasma leading to phenytoin toxicity. According to an NCBI report on Uremia, the annual diagnosis rate for end-stage renal disease (ESRD) is about 354 individuals in a million. High levels of phenytoin can also cause central nervous system (CNS) depression which slows down the neurological functions in the body. Phenytoin testing can be helpful in the detection of possible kidney failure and identifying the excess amount of the medicine in blood plasma before it affects the CNS. Thus its importance in the timely detection of potential damage to various body organs is a major factor supporting the increase in the phenytoin testing market.
-
Increased Rate of Epilepsy and Post-Surgical Complication Causing Seizures - More than 40 million people worldwide has epilepsy. It is evaluated that over 60% of people with epilepsy could live a life without seizures if diagnosed and treated at the right time. Phenytoin is widely used as an anticonvulsant, thus assisting the growth of the phenytoin testing market.
-
World Wide Expansion of Scope of Service by Key Service Providers – The number of lab tests conducted only in the United States each year is approximately 8 billion.
-
Rising Demand for Point-of-Care Testing – The global increase in chronic diseases and the growing incidences of Healthcare-Associated Infections (HAIs) following the Covid-19 hospitalizations have raised the demand for point-of-care testing, including phenytoin testing. According to the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) under the Centers for Disease Control and Prevention (CDC), 6 in 10 Americans suffer from at least one chronic disease. Concerning HAIs, it was observed that there was a rise in their incidences in 2021 compared to 2019.
-
Increased Awareness Programs by Non-Government Organizations About Drug Abuse and Drug Adherence – In 2019 alone, drug usage killed approximately a million people worldwide. In many parts of the world, NGOs complement governmental efforts to enhance awareness about treatments for drug abuse, including those by drug overdose, contributing to the growth of the phenytoin testing market size.
Challenges
-
Inconsistency of Test Results
-
Additional Expenditure on Regular Monitoring for Deciding Dosage of Phenytoin
-
Use of Alternative Medicines Owing to the Adverse Effects of Phenytoin
The global phenytoin testing market is segmented and analyzed for demand and supply by end-user into hospitals, pathological laboratories, and research centers. The hospitals segment among these is expected to hold the largest market share by the end of 2033 while observing the growing number of hospitals worldwide. In 2020, the total number of hospitals in the U.S. was estimated to be more than 6000, with the number of staffed beds crossing 9 lakhs.
Global Phenytoin Testing Market Regional Synopsis
Regionally, the global phenytoin testing market is studied into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033. The growth of the phenytoin testing market in North America can be primarily attributed to the increasing number of active epilepsy cases. Epilepsy affects approximately 3 million Americans, and each year close to 2 lakhs of the population are newly diagnosed with this brain disorder. Another factor that boosts the expansion of the phenytoin testing market in North America is the growth in the pathological laboratory business. The U.S. alone has about 30,000 diagnostic & medical laboratory businesses as of 2022. Additionally, the development of the healthcare infrastructure in the region leads the market to further growth.
Source: Kenneth Research
Market Segmentation
Our in-depth analysis of the global phenytoin testing market includes the following segments:
|
By Product Type |
|
|
By End-User |
|
Customize Report: Request Customization
Key Companies Dominating the Global Phenytoin Testing Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global phenytoin testing market that are included in our report are Abbott, ARUP Laboratories, Quest Diagnostics Incorporated, Lybrate Inc., Portea Medical, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Randox Laboratories Ltd., Personalabs, Roche Diagnostics, and others.
Global Phenytoin Testing Market: Latest Developments
-
January, 2022: Pfizer Inc. - shared its findings on the in vitro efficiency of its novel COVID-19 oral treatment, PAXLOVID, in treatment of the Omicron variant. However, the company has contraindicated the treatment with phenytoin, a potent CYP3A inducer directly increasing the demand for phenytoin testing.
-
January, 2022: Quest Diagnostics Incorporated - announced its new solution in collaboration with Walmart to let consumers purchase from over 50 laboratory tests, thus facilitating people to hold control over their healthcare. Quest Diagnostics is a chief player in the market for phenytoin testing.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Abbott
- ARUP Laboratories
- Quest Diagnostics Incorporated
- Lybrate Inc.
- Portea Medical
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Randox Laboratories Ltd.
- Personalabs
- Roche Diagnostics
Related Reports
Proof of Quality & Reliability
